Mind Cure adds a health supplements veteran to its product development team. Moonbeam mushrooms in final product testing.
Mind Cure adds a health supplements veteran to its product development team. Moonbeam mushrooms in final product testing.
Compass Pathways has closed its IPO financing, raising $146.6 million via the sale of 8,625,000 American Depository Shares.
Mind Cure's organic Moonbeam mushroom products are now eligible for sale in Canada.
PharmaDrug will assume control of its first Super Smart psychedelics store on October 1st.
Revive's corporate update centers on psilocybin research on a new delivery system and addiction treatment.
Numinus warrants have an exercise price of CAD$0.35 and are valid until September 10, 2022.
MindMed Inc has applied to up-list on the NASDAQ.
Canada stands out as the premier destination for psychedelic drug companies.
Newest IPO hits September 21- MCUR
Compass Pathways has upsized its IPO financing to $127.5 million, at an offering price of $17.00 per American Depositiry Share (ADS).
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now